Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia

References

• Reiner Ř. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10:453–464.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics – 2019 update: a report from the American Heart Association. Circulation. 2019. DOI:10.1161/CIR.0000000000000659.
   Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–1361.
   PubMed Web of Science ®Google Scholar
• Reiner Ř. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14:401–411.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology1. Circ Res. 2016;118:547–563.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Phillip S, Reynolds K, et al. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103:3019–3027.
   PubMed Web of Science ®Google Scholar
• Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiological mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6:391–409.
   PubMedGoogle Scholar
• Mori TA, Burke B, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidaemic men. Am J Clin Nutr. 2000;71:1085–1094.
   PubMed Web of Science ®Google Scholar
• Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:478–483.
   Web of Science ®Google Scholar
• Brinton EA, Mason RP. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids Health Dis. 2017;16:23.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008;39:2052–2058.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol. 2011;108:682–690.
   PubMed Web of Science ®Google Scholar
• Braeckman RA, Manku MS, Bays HE, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Fatty Acids. 2013;89:195–201.
   PubMed Web of Science ®Google Scholar
• Ennis JL, Cronwell WC. Clinical utility of low-density lipoprotein particles and apolipoprotein B in patients with cardiovascular risk. J Fam Pract. 2013;62(7 Suppl):1–8.
   PubMed Web of Science ®Google Scholar
• Wyler von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotin CIII: a systematic review and meta-analysis. J Clin Lipidol. 2015;9:498–510.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Obata JE, Hirano M, et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis. 2011;18:163–167.
   Google Scholar
• Bays HE, Braeckman RA, Ballantyne CM, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6:565–572.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10:635–645.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Phillip S, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016;253:81–87.
   PubMed Web of Science ®Google Scholar
• Mosca L, Ballantyne CM, Bays HE, et al. Usefulness of icosapent ethyl (eicosapentaenoic acid ethyl ester) in women to lower triglyceride levels (results from the MARINE and ANCHOR trials). Am J Cardiol. 2017;119:397–403.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–992.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Braeckman RA, Bays HE. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR study). J Clin Lipid. 2015;9:377–383.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulation markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;12:37–46.
   Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome. Metab Syndr Relat Disord. 2015;13:239–247.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
   PubMed Web of Science ®Google Scholar
• Randomized trial for evaluation in secondary prevention efficacy of combination therapy – statin and eicosapentaenoic acid UMIN-CTR Clinical Trial. [cited 2019 Apr 05]. Avialable from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014051
   Google Scholar
• Doi M, Nosaka K, Miyoshi T, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. Int J Cardiol. 2014;176:577–582.
   PubMed Web of Science ®Google Scholar
• Nosaka K, Miyoshi T, Iwamoto M, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1 year outcomes of a randomized controlled study. Int J Cardiol. 2017;228:173–179.
   PubMed Web of Science ®Google Scholar
• Nishio R, Shinke T, Otake H, et al. Stabilising effect of eicosapentaenoic acid and statin therapy on coronary thin-can fibroatheroma. Atherosclerosis. 2014;234:114–119.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70:537–544.
   PubMed Web of Science ®Google Scholar
• Larson MK, Tormoen GW, Weaver LJ, et al. Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation. Am J Physiol Cell Physiol. 2013;304:C273–C279.
   PubMed Web of Science ®Google Scholar
• Morales-Martinez A, Zamarano-Carrillo A, Montes S, et al. Rich fatty acids diet of fish and olive oils modifies membrane properties in striatal rat synaptosomes. Nutr Neurosci. 2019;1–12. DOI:10.1080/1028415X.2019.158692.
   PubMedGoogle Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016; 11:CD009753.
   PubMedGoogle Scholar
• Wang D, Liu B, Tao W, et al. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev. 2015; 10:CD009580.
   Google Scholar
• Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;26:521–538.
   Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107.
   PubMed Web of Science ®Google Scholar